Predictive markers for progessive disease progression in Acne Inversa (AI)/Hidradentitis Suppurativa (HS) patients

Predictive markers for progessive disease progression in Acne Inversa (AI)/Hidradentitis Suppurativa (HS) patients - PIRANHA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013778

Enrollment

500

Registered

2018-01-26

Start date

2016-06-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACNEINVERSA L73 L73.2

Interventions

Group 1: Prospective, epidemiological, non interventional, study in a multicentric way. Observation cohort for the long-term documentation of the AI/ HS (Acne inversa/ Hidradenitis suppurativa): 500 p

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with confirmed diagnosis of acne inversa/ Hidradenitis suppurativa

Exclusion criteria

Exclusion criteria: Illiteracy or language skills not sufficient (German), in order to fill the questionnaires

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the study is the proportion of patients showing disease progression at 12 months follow-up defined as worsening in HS-PGA, Hurley-Score and AN count (abscesses and inflammatory nodules), while the need for invasive surgical intervention is an absolute progression parameter for all definitions.	—

Secondary

Measure	Time frame
Selection: - Identification of factors associated with disease progression - Proportion of patients who have progressed and do not receive effective regimens according to the S1 guideline for HS/HS therapy - duration to progression - Proportion of patients who show a worsening (e.g., a worsening of the Hurley score by at least one unit from baseline) of their HS/HS disease. - Proportion of patients requiring large-scale surgery. - proportion of patients who have achieved improvement without surgery. - factors associated with improvement of the disease. Record on burden of disease - Pain (NRS) - Quality of life (DLQI) - General health status (SF-12) - Working ability (WAPI, WAI) - Comorbidities HS/HS care parameters - Number of previous misdiagnoses - Number of visits to physicians before diagnosis - Time to diagnosis	—

Measure

Time frame

Selection: - Identification of factors associated with disease progression - Proportion of patients who have progressed and do not receive effective regimens according to the S1 guideline for HS/HS therapy - duration to progression - Proportion of patients who show a worsening (e.g., a worsening of the Hurley score by at least one unit from baseline) of their HS/HS disease. - Proportion of patients requiring large-scale surgery. - proportion of patients who have achieved improvement without surgery. - factors associated with improvement of the disease. Record on burden of disease - Pain (NRS) - Quality of life (DLQI) - General health status (SF-12) - Working ability (WAPI, WAI) - Comorbidities HS/HS care parameters - Number of previous misdiagnoses - Number of visits to physicians before diagnosis - Time to diagnosis

—

Countries

Germany

Contacts

Public ContactSusana Gomis-Kleindienst

AbbVie Deutschland GmbH & Co. KG

susana.gomis-kleindienst@abbvie.com+496111720

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026